News
The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...
According to the Financial Times, MSD – known as Merck & Co in the US and Canada – is in the final stages of a $10 billion ...
Whether stemming from early childhood adversity, combat exposure, or interpersonal abuse, trauma leaves long-term imprints on ...
Improving efficiencies and uncomplicating processes are critical to the future success of NHS Trusts across the country. The ...
Boehringer Ingelheim has raised hopes of a more patient-friendly option with the start of phase 2 testing of BI 1815368, ...
Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...
The second annual HLTH Europe conference brought together health leaders, start-ups, investors, and developers from across the globe for a mid-year pulse check on where healthcare innovation stands ...
A new formulation of Novartis' antimalarial Coartem has become the first medicine to be approved for use in very young ...
Medistry LLC is the internet registry operator of the .med top level domain (TLD). Currently in a period of pre-registration ...
BIO Boston: 2025 is shaping up to be a year of challenge – but also opportunity – say biotech bosses
So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...
South Korean electronics giant Samsung has continued a push into the health category with an agreement to buy Xealth, a ...
Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results